After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Last year, I wrote about pharmaceutical company Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ). I labeled it a buy based on expected growth with the acquisition of BAQSIMI, but with market pessimism surrounding the healthcare industry, the stock’s performance just wasn’t there, and insteadI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well ...